Anna Małecka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anna Małecka has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
- Ninela Irga-Jaworska
Department of Pediatrics, Hematology and Oncology, Medical University of Gdansk, 80-210 Gdansk, Poland
6 shared publications - Katarzyna Derwich
Department of Pediatric Oncology, Hematology and Transplantology, Institute of Pediatrics, Poznan University of Medical Sciences, 60-572 Poznan, Poland
4 shared publications Radoslaw Jaworski
Department of Paediatric Cardiology and Congenital Heart Defects Medical University of Gdansk Gdansk Poland
4 shared publications- Tomasz Szczepański
Department of Pediatric Hematology and Oncology, Medical University of Silesia in Katowice, ul. 3 Maja 13-15, 41-800 Zabrze, Poland
4 shared publications - Grażyna Karolczyk
Department of Pediatric Hematology and Oncology, Regional Polyclinic Hospital in Kielce, 25-734 Kielce, Poland
3 shared publications - Jan Styczyński
Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz, Poland
3 shared publications
Latest Publications
- Open Access
- 1 February 2026
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 18, 1-13
Hypertriglyceridemia During Anticancer Therapy in Pediatric Patients with Acute Lymphoblastic Leukemia – A Nationwide Experience
In this study, we aimed to assess the demographics and incidence of hypertriglyceridemia (HTG) during acute lymphoblastic leukemia (ALL) treatment, complications related to HTG, and the treatment strategies applied in pediatric patients treated in pediatric hemato-oncology centers in Poland. A total of 72 out of 641 children, aged <18 years with ALL were diagnosed with HTG as a treatment-related complication. Statistical analyses were conducted with a significance level of α = 0.05. The emergence of HTG is a significant complication, with median peak triglyceride levels during treatment reaching 1385.00 mg/dL. Only 5.56% (n = 4) experienced complications. No patients developed pancreatitis. Treatment interruptions were minimal (a median 5.67 days). No children died due to HTG. Management strategies for HTG management included plasmapheresis in 8.3% (n = 6/72). Other therapies – insulin (23.6%, n = 17), heparin (34.7%, n = 25), fibrates (41.7%, n = 30), and omega-3 fatty acids (58.3%, n = 45). A correlation was observed between low antithrombin levels and high TG levels. This is the first nationwide, multicenter analysis conducted across pediatric hemato-oncology centers in Poland evaluating HTG during ALL therapy. HTG occurred in 11.1% of children in the analyzed cohort, and 72% of these cases were grade 3 or 4. With the management strategies applied, severe complications were uncommon and chemotherapy interruptions were generally short. Our findings support the effective triglyceride monitoring; however, triglyceride measurements are currently not standardized and are not performed at predefined time points during treatment. The observed association between low antithrombin levels and high triglyceride concentrations may help identify patients who require closer surveillance. Further prospective studies are needed to define risk factors, optimize prevention and treatment strategies and explore long-term outcomes.
- 1 February 2026
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 18, 1-13
Open AccessHypertriglyceridemia During Anticancer Therapy in Pediatric Patients with Acute Lymphoblastic Leukemia – A Nationwide Experience
In this study, we aimed to assess the demographics and incidence of hypertriglyceridemia (HTG) during acute lymphoblastic leukemia (ALL) treatment, complications related to HTG, and the treatment strategies applied in pediatric patients treated in pediatric hemato-oncology centers in Poland. A total of 72 out of 641 children, aged <18 years with ALL were diagnosed with HTG as a treatment-related complication. Statistical analyses were conducted with a significance level of α = 0.05. The emergence of HTG is a significant complication, with median peak triglyceride levels during treatment reaching 1385.00 mg/dL. Only 5.56% (n = 4) experienced complications. No patients developed pancreatitis. Treatment interruptions were minimal (a median 5.67 days). No children died due to HTG. Management strategies for HTG management included plasmapheresis in 8.3% (n = 6/72). Other therapies – insulin (23.6%, n = 17), heparin (34.7%, n = 25), fibrates (41.7%, n = 30), and omega-3 fatty acids (58.3%, n = 45). A correlation was observed between low antithrombin levels and high TG levels. This is the first nationwide, multicenter analysis conducted across pediatric hemato-oncology centers in Poland evaluating HTG during ALL therapy. HTG occurred in 11.1% of children in the analyzed cohort, and 72% of these cases were grade 3 or 4. With the management strategies applied, severe complications were uncommon and chemotherapy interruptions were generally short. Our findings support the effective triglyceride monitoring; however, triglyceride measurements are currently not standardized and are not performed at predefined time points during treatment. The observed association between low antithrombin levels and high triglyceride concentrations may help identify patients who require closer surveillance. Further prospective studies are needed to define risk factors, optimize prevention and treatment strategies and explore long-term outcomes.
- 1 January 2026
- Published by Wiley in Pediatrics International
- Vol. 68 (1) , e70339
Successful ECMO in an immunocompromised child with ALL , sepsis, and pneumonia
- 1 January 2026
- Published by Wiley in Pediatrics International
- Vol. 68 (1) , e70339
Successful ECMO in an immunocompromised child with ALL , sepsis, and pneumonia
- Open Access
Posterior Reversible Encephalopathy Syndrome in Children with Malignancies or After Hematopoietic Cell Transplantation: A Polish Nationwide Study
Background/Objectives: The objective of this study was to analyze the clinical and laboratory features, management, outcomes, and complications of PRES in children with malignancies or following hematopoietic cell transplantation (HCT). Methods: This was a multicenter retrospective analysis of PRES episodes diagnosed between 2014 and 2022 in Polish pediatric hematology and oncology (PHO) centers and HCT units. The study included 438 patients treated for malignancy or post-HCT: 120 with PRES (study group) and 318 without PRES (control group). Results: PRES was diagnosed in children aged 1.7–16.5 years (median = 7.7 years). The most common underlying diagnosis was ALL (76.7%; n = 92). Symptoms of PRES included disturbances of consciousness (84.2%), seizures (80.0%), hypertension (74.2%), apathy (64.2%), abdominal pain (45.0%), visual disturbances (28.3%), and headaches (26.7%). Electrolyte abnormalities were observed in 75.0% of children, most commonly hyponatremia (49.2%) and hypokalemia (37.5%). Children with PRES were more likely to require admission to the intensive care unit (ICU) than controls (50.0% vs. 29.6%, p < 0.001). The most frequent long-term complications of PRES were hypertension (22.5%) and epilepsy (20.8%). Among PHO patients, those with PRES had significantly lower DFS (76.7% vs. 93.7%, p < 0.001) and OS (79.2% vs. 93.4%, p < 0.001). In the HCT group, PRES was also associated with lower DFS (40.0% vs. 83.3%, p = 0.012) and OS (40.0% vs. 77.8%, p = 0.047). Conclusions: PRES is a significant complication of oncological and transplant treatment in children. Its occurrence was associated with worse overall and disease-free survival. We proposed a predictive index for PRES, diagnostic criteria, and a revised name for this syndrome.
Open AccessPosterior Reversible Encephalopathy Syndrome in Children with Malignancies or After Hematopoietic Cell Transplantation: A Polish Nationwide Study
Background/Objectives: The objective of this study was to analyze the clinical and laboratory features, management, outcomes, and complications of PRES in children with malignancies or following hematopoietic cell transplantation (HCT). Methods: This was a multicenter retrospective analysis of PRES episodes diagnosed between 2014 and 2022 in Polish pediatric hematology and oncology (PHO) centers and HCT units. The study included 438 patients treated for malignancy or post-HCT: 120 with PRES (study group) and 318 without PRES (control group). Results: PRES was diagnosed in children aged 1.7–16.5 years (median = 7.7 years). The most common underlying diagnosis was ALL (76.7%; n = 92). Symptoms of PRES included disturbances of consciousness (84.2%), seizures (80.0%), hypertension (74.2%), apathy (64.2%), abdominal pain (45.0%), visual disturbances (28.3%), and headaches (26.7%). Electrolyte abnormalities were observed in 75.0% of children, most commonly hyponatremia (49.2%) and hypokalemia (37.5%). Children with PRES were more likely to require admission to the intensive care unit (ICU) than controls (50.0% vs. 29.6%, p < 0.001). The most frequent long-term complications of PRES were hypertension (22.5%) and epilepsy (20.8%). Among PHO patients, those with PRES had significantly lower DFS (76.7% vs. 93.7%, p < 0.001) and OS (79.2% vs. 93.4%, p < 0.001). In the HCT group, PRES was also associated with lower DFS (40.0% vs. 83.3%, p = 0.012) and OS (40.0% vs. 77.8%, p = 0.047). Conclusions: PRES is a significant complication of oncological and transplant treatment in children. Its occurrence was associated with worse overall and disease-free survival. We proposed a predictive index for PRES, diagnostic criteria, and a revised name for this syndrome.
- 31 July 2025
- Published by Polish Chemical Society in Wiadomości Chemiczne
- Vol. 79 (7-8) , 505-520
Rola szlaków molekularnych i mikrośrodowiska w patogenezie i progresji białaczek
Leukemias are a heterogeneous group of hematologic malignancies characterized by clonal proliferation of bone marrow progenitor cells and classified into acute and chronic, which differ in their biology, epidemiology, and clinical course. Leukemias are currently the most common type of childhood cancer. Biochemically, leukemia involves genetic alterations, metabolic dysregulation, and microenvironmental interactions. Genomic alterations in leukemic cells result from chromosomal translocations, point mutations in oncogenes and tumor suppressors as well as epigenetic modifications. Such changes may affect cell survival and differentiation programs. Additionally, the dysregulation of key signaling pathways contributes to redox homeostasis and fosters survival under oxidative stress conditions. Leukemic cells often exhibit metabolic reprogramming towards enhanced glycolysis and altered amino acid metabolism to support rapid proliferation, whereas the leukemic bone marrow niche provides crucial survival signals through stromal interactions and cytokine secretion, promoting chemoresistance and leukemic adaptation to microenvironmental constraints. Despite the dynamic progress in research and the increasing efficacy of selected therapeutic modalities, disease relapse and treatment resistance remain major challenges. Due to the heterogeneity of leukemias and the resulting diversity of molecular mechanisms, this study presents selected aspects useful for understanding the complexity of their pathogenesis and clinical course. A comprehensive analysis of features characteristic of this group of malignancies, combined with a multidisciplinary approach, contributes to a deeper insight into leukemia biochemistry and facilitates the identification of potential targets for modern therapeutic strategies.
- 31 July 2025
- Published by Polish Chemical Society in Wiadomości Chemiczne
- Vol. 79 (7-8) , 505-520
Rola szlaków molekularnych i mikrośrodowiska w patogenezie i progresji białaczek
Leukemias are a heterogeneous group of hematologic malignancies characterized by clonal proliferation of bone marrow progenitor cells and classified into acute and chronic, which differ in their biology, epidemiology, and clinical course. Leukemias are currently the most common type of childhood cancer. Biochemically, leukemia involves genetic alterations, metabolic dysregulation, and microenvironmental interactions. Genomic alterations in leukemic cells result from chromosomal translocations, point mutations in oncogenes and tumor suppressors as well as epigenetic modifications. Such changes may affect cell survival and differentiation programs. Additionally, the dysregulation of key signaling pathways contributes to redox homeostasis and fosters survival under oxidative stress conditions. Leukemic cells often exhibit metabolic reprogramming towards enhanced glycolysis and altered amino acid metabolism to support rapid proliferation, whereas the leukemic bone marrow niche provides crucial survival signals through stromal interactions and cytokine secretion, promoting chemoresistance and leukemic adaptation to microenvironmental constraints. Despite the dynamic progress in research and the increasing efficacy of selected therapeutic modalities, disease relapse and treatment resistance remain major challenges. Due to the heterogeneity of leukemias and the resulting diversity of molecular mechanisms, this study presents selected aspects useful for understanding the complexity of their pathogenesis and clinical course. A comprehensive analysis of features characteristic of this group of malignancies, combined with a multidisciplinary approach, contributes to a deeper insight into leukemia biochemistry and facilitates the identification of potential targets for modern therapeutic strategies.
- Open Access
- 31 March 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (7) , 2029
Pre-Exposure Prophylaxis and Treatment with Tixagevimab/Cilgavimab for COVID-19 among Immunocompromised Pediatric Patients
Background: Patients treated with hemato-oncological malignancies (HO) or undergoing cellular therapies such as hematopoietic stem cell transplantation (HSCT) or chimeric antigen receptor T cells (CAR-T) were significantly affected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite the success of SARS-CoV-2 vaccination, immunocompromised patients remain at increased risk for severe coronavirus disease (COVID-19), rendering this group of population a high priority for additional prevention and treatment options. Tixagevimab and Cilgavimab (TIXA/CILGA, AZD7442, Evusheld®) is a combination of two fully human, long-acting monoclonal antibodies. TIXA/CILGA have been approved as pre-exposure prophylaxis and treatment in patients at risk of severe disease with impaired vaccine response. Our objective was to describe the efficacy and safety among immunocompromised pediatric patients. Methods: This was an observational multicenter cohort study of immunocompromised pediatric patients receiving TIXA/CILGA conducted at nine Polish centers of Pediatric Oncology, Hematology and Bone Marrow Transplantation. We analyzed patients in two groups; those treated with HO and those undergoing cellular therapies: HSCT or CAR-T cells. In addition, two other cohorts were identified: patients given TIXA/CILGA as pre-exposure prophylactic and therapeutic intervention. Results: A total of 78 patients were evaluated during the study period: 69 (88.5%) received TIXA/CILGA as pre-exposure prophylaxis and 9 (11.5%) as a treatment strategy. A total of 52 (66.6%) patients were treated with standard chemotherapy at HO departments; 21 (27%) underwent HSCT, and 5 (6.4%) received CAR-T cell therapy. All children with COVID-19 receiving TIXA/CILGA presented a mild degree of severity. The most common clinical manifestations were fever, cough and coryza. At least one adverse event (AE) was reported in two (3.8%) patients excluding standard injection site reactions. Reported AEs were mild or moderate in intensity. One child reported mild myalgia and one reported moderate bone pain and weakness. Conclusions: In our observational multicenter cohort study, we explored the use of TIXA/CILGA as pre-exposure prophylaxis and treatment for COVID-19 among immunocompromised pediatric patients. While our findings suggest a potential benefit in preventing and managing COVID-19 in this vulnerable population, it is important to note the study’s non-comparative design. Our results highlight the need for well-designed clinical trials to confirm these observations and further assess the efficacy and safety of TIXA/CILGA in immunocompromised children.
- 31 March 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (7) , 2029
Open AccessPre-Exposure Prophylaxis and Treatment with Tixagevimab/Cilgavimab for COVID-19 among Immunocompromised Pediatric Patients
Background: Patients treated with hemato-oncological malignancies (HO) or undergoing cellular therapies such as hematopoietic stem cell transplantation (HSCT) or chimeric antigen receptor T cells (CAR-T) were significantly affected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite the success of SARS-CoV-2 vaccination, immunocompromised patients remain at increased risk for severe coronavirus disease (COVID-19), rendering this group of population a high priority for additional prevention and treatment options. Tixagevimab and Cilgavimab (TIXA/CILGA, AZD7442, Evusheld®) is a combination of two fully human, long-acting monoclonal antibodies. TIXA/CILGA have been approved as pre-exposure prophylaxis and treatment in patients at risk of severe disease with impaired vaccine response. Our objective was to describe the efficacy and safety among immunocompromised pediatric patients. Methods: This was an observational multicenter cohort study of immunocompromised pediatric patients receiving TIXA/CILGA conducted at nine Polish centers of Pediatric Oncology, Hematology and Bone Marrow Transplantation. We analyzed patients in two groups; those treated with HO and those undergoing cellular therapies: HSCT or CAR-T cells. In addition, two other cohorts were identified: patients given TIXA/CILGA as pre-exposure prophylactic and therapeutic intervention. Results: A total of 78 patients were evaluated during the study period: 69 (88.5%) received TIXA/CILGA as pre-exposure prophylaxis and 9 (11.5%) as a treatment strategy. A total of 52 (66.6%) patients were treated with standard chemotherapy at HO departments; 21 (27%) underwent HSCT, and 5 (6.4%) received CAR-T cell therapy. All children with COVID-19 receiving TIXA/CILGA presented a mild degree of severity. The most common clinical manifestations were fever, cough and coryza. At least one adverse event (AE) was reported in two (3.8%) patients excluding standard injection site reactions. Reported AEs were mild or moderate in intensity. One child reported mild myalgia and one reported moderate bone pain and weakness. Conclusions: In our observational multicenter cohort study, we explored the use of TIXA/CILGA as pre-exposure prophylaxis and treatment for COVID-19 among immunocompromised pediatric patients. While our findings suggest a potential benefit in preventing and managing COVID-19 in this vulnerable population, it is important to note the study’s non-comparative design. Our results highlight the need for well-designed clinical trials to confirm these observations and further assess the efficacy and safety of TIXA/CILGA in immunocompromised children.
- Open Access
- 31 January 2024
- Published by Wiley
The Vitamin D Status in Children with Newly Diagnosed Acute Lymphoblastic Leukaemia and its Potential Impact on Primary Symptoms of Leukaemia and Course of Induction Treatment.
Background: The vitamin D deficiency is ubiquitous among children population. Similar problem is recognized among paediatric patients with acute lymphoblastic leukaemia. The purpose of this study was to analyze the prevalence of vitamin D deficiency and investigate the connection between vitamin D status and course of induction treatment of ALL. Methods: A cross-sectional study including 59 patients with newly diagnosed ALL from May 2017 until November 2020. Results: The vitamin D insufficiency was found in 36% of patients. There were no seasonal differences in vitamin D status. Patients with optimal 25(OH)D concentration presented more profound thrombocytopenia (p=.015) and required more frequent platelet transfusions (p=0.018). The good prognosis factors as B phenotype and hyperdiploidy were also more frequent among children with higher 25(OH)D concentration (p=0.01 and p=0.014, respectively). Conclusion: The study displayed that patients with higher serum concentration of 25(OH)D presented deeper thrombocytopenia and needed more frequent transfusions. Moreover, those patients showed higher rates of B-cell leukaemia and hyperdiploid karyotype. We did not find any influence of potential sunlight exposure (defined as the season of the year at admission) on serum 25(OH)D, which supports the supplementing of vitamin D throughout the entire year. Moreover, the supplementation of vitamin D seems to be safe in the context of renal complications connected to calcium and phosphorus imbalance as no correlation between their levels and 25(OH)D concentration was found.
- 31 January 2024
- Published by Wiley
Open AccessThe Vitamin D Status in Children with Newly Diagnosed Acute Lymphoblastic Leukaemia and its Potential Impact on Primary Symptoms of Leukaemia and Course of Induction Treatment.
Background: The vitamin D deficiency is ubiquitous among children population. Similar problem is recognized among paediatric patients with acute lymphoblastic leukaemia. The purpose of this study was to analyze the prevalence of vitamin D deficiency and investigate the connection between vitamin D status and course of induction treatment of ALL. Methods: A cross-sectional study including 59 patients with newly diagnosed ALL from May 2017 until November 2020. Results: The vitamin D insufficiency was found in 36% of patients. There were no seasonal differences in vitamin D status. Patients with optimal 25(OH)D concentration presented more profound thrombocytopenia (p=.015) and required more frequent platelet transfusions (p=0.018). The good prognosis factors as B phenotype and hyperdiploidy were also more frequent among children with higher 25(OH)D concentration (p=0.01 and p=0.014, respectively). Conclusion: The study displayed that patients with higher serum concentration of 25(OH)D presented deeper thrombocytopenia and needed more frequent transfusions. Moreover, those patients showed higher rates of B-cell leukaemia and hyperdiploid karyotype. We did not find any influence of potential sunlight exposure (defined as the season of the year at admission) on serum 25(OH)D, which supports the supplementing of vitamin D throughout the entire year. Moreover, the supplementation of vitamin D seems to be safe in the context of renal complications connected to calcium and phosphorus imbalance as no correlation between their levels and 25(OH)D concentration was found.
- Open Access
- 3 August 2023
- Published by VM Media Group sp. z o.o in Acta Haematologica Polonica
Hypertriglyceridemia associated with anticancer therapy based on asparaginase and steroids: a retrospective single center study of children with acute lymphoblastic leukemia and lymphoblastic lymphoma
Introduction: Hypertriglyceridemia (HTG) is one of the common complications of the regimens based on steroids and asparaginase used in the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in children. The aim of this cross-sectional retrospective study was the analysis of the prevalence, clinical course and management of hypertriglyceridemia following the administration of asparaginase and steroids according to the binding protocols. Material and methods: A cohort of 75 children with ALL or LBL was analyzed with reference to anthropometric and laboratory parameters, clinical symptoms, implemented treatment, and complications. Results: The prevalence of HTG in the analyzed cohort was 29.3%. Risk factors for HTG development were older age, cachexia and lower body mass index, but there was no correlation with high risk group. Patients with HTG presented with elevated lipase acivity and total cholesterol concentration and decreased antithrombin, albumin, sodium and high-density lipoprotein cholesterol. Reported symptoms were unspecific. Management of HTG included: omega 3 fatty acids, fibrates, insulin and plasmapheresis. Conclusions: Hypertriglyceridemia is a significant complication of ALL and LBL treatment, and can lead to acute and late complications and cause unwelcome interruptions to therapy that can lead to poorer outcomes of treatment. As the course of HTG is oligosymptomatic, but can have undesirable repercussions, every patient receiving asparaginase with steroids should be monitored for HTG. It is also noteworthy that HTG can occur three or more weeks after asparaginase administration. Introduction: Hypertriglyceridemia (HTG) is one of the common complications of the regimens based on steroids and asparaginase used in the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in children. The aim of this cross-sectional retrospective study was the analysis of the prevalence, clinical course and management of hypertriglyceridemia following the administration of asparaginase and steroids according to the binding protocols. Material and methods: A cohort of 75 children with ALL or LBL was analyzed with reference to anthropometric and laboratory parameters, clinical symptoms, implemented treatment, and complications. Results: The prevalence of HTG in the analyzed cohort was 29.3%. Risk factors for HTG development were older age, cachexia and lower body mass index, but there was no correlation with high risk group. Patients with HTG presented with elevated lipase acivity and total cholesterol concentration and decreased antithrombin, albumin, sodium and high-density lipoprotein cholesterol. Reported symptoms were unspecific. Management of HTG included: omega 3 fatty acids, fibrates, insulin and plasmapheresis. Conclusions: Hypertriglyceridemia is a significant complication of ALL and LBL treatment, and can lead to acute and late complications and cause unwelcome interruptions to therapy that can lead to poorer outcomes of treatment. As the course of HTG is oligosymptomatic, but can have undesirable repercussions, every patient receiving asparaginase with steroids should be monitored for HTG. It is also noteworthy that HTG can occur three or more weeks after asparaginase administration.
- 3 August 2023
- Published by VM Media Group sp. z o.o in Acta Haematologica Polonica
Open AccessHypertriglyceridemia associated with anticancer therapy based on asparaginase and steroids: a retrospective single center study of children with acute lymphoblastic leukemia and lymphoblastic lymphoma
Introduction: Hypertriglyceridemia (HTG) is one of the common complications of the regimens based on steroids and asparaginase used in the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in children. The aim of this cross-sectional retrospective study was the analysis of the prevalence, clinical course and management of hypertriglyceridemia following the administration of asparaginase and steroids according to the binding protocols. Material and methods: A cohort of 75 children with ALL or LBL was analyzed with reference to anthropometric and laboratory parameters, clinical symptoms, implemented treatment, and complications. Results: The prevalence of HTG in the analyzed cohort was 29.3%. Risk factors for HTG development were older age, cachexia and lower body mass index, but there was no correlation with high risk group. Patients with HTG presented with elevated lipase acivity and total cholesterol concentration and decreased antithrombin, albumin, sodium and high-density lipoprotein cholesterol. Reported symptoms were unspecific. Management of HTG included: omega 3 fatty acids, fibrates, insulin and plasmapheresis. Conclusions: Hypertriglyceridemia is a significant complication of ALL and LBL treatment, and can lead to acute and late complications and cause unwelcome interruptions to therapy that can lead to poorer outcomes of treatment. As the course of HTG is oligosymptomatic, but can have undesirable repercussions, every patient receiving asparaginase with steroids should be monitored for HTG. It is also noteworthy that HTG can occur three or more weeks after asparaginase administration. Introduction: Hypertriglyceridemia (HTG) is one of the common complications of the regimens based on steroids and asparaginase used in the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in children. The aim of this cross-sectional retrospective study was the analysis of the prevalence, clinical course and management of hypertriglyceridemia following the administration of asparaginase and steroids according to the binding protocols. Material and methods: A cohort of 75 children with ALL or LBL was analyzed with reference to anthropometric and laboratory parameters, clinical symptoms, implemented treatment, and complications. Results: The prevalence of HTG in the analyzed cohort was 29.3%. Risk factors for HTG development were older age, cachexia and lower body mass index, but there was no correlation with high risk group. Patients with HTG presented with elevated lipase acivity and total cholesterol concentration and decreased antithrombin, albumin, sodium and high-density lipoprotein cholesterol. Reported symptoms were unspecific. Management of HTG included: omega 3 fatty acids, fibrates, insulin and plasmapheresis. Conclusions: Hypertriglyceridemia is a significant complication of ALL and LBL treatment, and can lead to acute and late complications and cause unwelcome interruptions to therapy that can lead to poorer outcomes of treatment. As the course of HTG is oligosymptomatic, but can have undesirable repercussions, every patient receiving asparaginase with steroids should be monitored for HTG. It is also noteworthy that HTG can occur three or more weeks after asparaginase administration.
- 19 October 2022
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 45 (1) , e4-e8
The Vitamin D Status in Children With Newly Diagnosed Acute Lymphoblastic Leukemia and Its Potential Impact on the Primary Symptoms of Leukemia and Course of Induction Treatment
Background: Vitamin D deficiency is ubiquitous within the population of children. A similar problem is recognized among pediatric patients with acute lymphoblastic leukemia. The purpose of this study was to analyze the prevalence of vitamin D deficiency and to investigate the connection between vitamin D status and the course of induction treatment of ALL. Materials and Methods: A cross-sectional study including 59 patients with newly diagnosed ALL from May 2017 until November 2020. Results: Vitamin D deficiency was found in 39% of the patients. There were no seasonal differences in vitamin D status. Patients with optimal 25(OH)D concentration presented more profound thrombocytopenia (P=0.015) and required more frequent platelet transfusions (P=0.018). Good prognosis factors such as B phenotype and hyperdiploidy were also more frequent among children with higher 25(OH)D concentration (P=0.01 and 0.014, respectively). Conclusions: The study showed that patients with a higher serum concentration of 25(OH)D presented deeper thrombocytopenia and needed more frequent transfusions. Moreover, those patients showed higher rates of B-cell leukemia and hyperdiploid karyotype. We did not find any influence of the possible exposure to sunlight (defined as the season of the year on admission) on serum 25(OH)D concentration, which supports the argument for supplementing vitamin D all year round. Moreover, the supplementing of vitamin D seems to be safe and does not cause any renal complications connected to calcium and phosphorus imbalance as no correlation between their levels and 25(OH)D concentration was found.
- 19 October 2022
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 45 (1) , e4-e8
The Vitamin D Status in Children With Newly Diagnosed Acute Lymphoblastic Leukemia and Its Potential Impact on the Primary Symptoms of Leukemia and Course of Induction Treatment
Background: Vitamin D deficiency is ubiquitous within the population of children. A similar problem is recognized among pediatric patients with acute lymphoblastic leukemia. The purpose of this study was to analyze the prevalence of vitamin D deficiency and to investigate the connection between vitamin D status and the course of induction treatment of ALL. Materials and Methods: A cross-sectional study including 59 patients with newly diagnosed ALL from May 2017 until November 2020. Results: Vitamin D deficiency was found in 39% of the patients. There were no seasonal differences in vitamin D status. Patients with optimal 25(OH)D concentration presented more profound thrombocytopenia (P=0.015) and required more frequent platelet transfusions (P=0.018). Good prognosis factors such as B phenotype and hyperdiploidy were also more frequent among children with higher 25(OH)D concentration (P=0.01 and 0.014, respectively). Conclusions: The study showed that patients with a higher serum concentration of 25(OH)D presented deeper thrombocytopenia and needed more frequent transfusions. Moreover, those patients showed higher rates of B-cell leukemia and hyperdiploid karyotype. We did not find any influence of the possible exposure to sunlight (defined as the season of the year on admission) on serum 25(OH)D concentration, which supports the argument for supplementing vitamin D all year round. Moreover, the supplementing of vitamin D seems to be safe and does not cause any renal complications connected to calcium and phosphorus imbalance as no correlation between their levels and 25(OH)D concentration was found.
- Open Access
Clinical Outcome in Pediatric Patients with Philadelphia Chromosome Positive ALL Treated with Tyrosine Kinase Inhibitors Plus Chemotherapy—The Experience of a Polish Pediatric Leukemia and Lymphoma Study Group
The treatment of children with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL Ph+) is currently unsuccessful. The use of tyrosine kinase inhibitors (TKIs) combined with chemotherapy has modernized ALL Ph+ therapy and appears to improve clinical outcome. We report herein the toxicity events and results of children with ALL Ph+ treated according to the EsPhALL2010 protocol (the European intergroup study of post-induction treatment of Philadelphia chromosome positive ALL) in 15 hemato-oncological centers in Poland between the years 2012 and 2019. The study group included 31 patients, aged 1–18 years, with newly diagnosed ALL Ph+. All patients received TKIs. Imatinib was used in 30 patients, and ponatinib was applied in one child due to T315I and M244V mutation. During therapy, imatinib was replaced with dasatinib in three children. The overall survival of children with ALL Ph+ treated according to the EsPhALL2010 protocol was 74.1% and event-free survival was 54.2% after five years. The cumulative death risk of the study group at five years was estimated at 25.9%, and its cumulative relapse risk was 30%. Our treatment outcomes are still disappointing compared to other reports. Improvements in supportive care and emphasis placed on the determination of minimal residual disease at successive time points, which will impact decisions on therapy, may be required.
Open AccessClinical Outcome in Pediatric Patients with Philadelphia Chromosome Positive ALL Treated with Tyrosine Kinase Inhibitors Plus Chemotherapy—The Experience of a Polish Pediatric Leukemia and Lymphoma Study Group
The treatment of children with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL Ph+) is currently unsuccessful. The use of tyrosine kinase inhibitors (TKIs) combined with chemotherapy has modernized ALL Ph+ therapy and appears to improve clinical outcome. We report herein the toxicity events and results of children with ALL Ph+ treated according to the EsPhALL2010 protocol (the European intergroup study of post-induction treatment of Philadelphia chromosome positive ALL) in 15 hemato-oncological centers in Poland between the years 2012 and 2019. The study group included 31 patients, aged 1–18 years, with newly diagnosed ALL Ph+. All patients received TKIs. Imatinib was used in 30 patients, and ponatinib was applied in one child due to T315I and M244V mutation. During therapy, imatinib was replaced with dasatinib in three children. The overall survival of children with ALL Ph+ treated according to the EsPhALL2010 protocol was 74.1% and event-free survival was 54.2% after five years. The cumulative death risk of the study group at five years was estimated at 25.9%, and its cumulative relapse risk was 30%. Our treatment outcomes are still disappointing compared to other reports. Improvements in supportive care and emphasis placed on the determination of minimal residual disease at successive time points, which will impact decisions on therapy, may be required.
- Open Access
- 23 July 2018
- Published by Springer Nature in Mycopathologia
- Vol. 184 (1) , 81-88
Isavuconazole in a Successful Combination Treatment of Disseminated Mucormycosis in a Child with Acute Lymphoblastic Leukaemia and Generalized Haemochromatosis: A Case Report and Review of the Literature
Invasive mucormycosis in immunocompromised children is a life-threatening fungal infection. We report a case of a 7-year-old girl treated for acute lymphoblastic leukaemia complicated by disseminated mucormycosis during induction therapy. Microscopic examination of surgically removed lung tissue revealed wide, pauci-septate hyphae suggesting a Mucorales infection. This diagnosis was confirmed immunohistochemically and by PCR analysis followed by a final identification of Cunninghamella sp. The patient was treated successfully with surgical debridement and antifungal combination therapy with amphotericin B, caspofungin and isavuconazole. The use of isavuconazole in a child was not previously reported. Additionally, case reports concerning pulmonary mucormycoses in paediatric population published after 2010 were reviewed. Nineteen out of 26 identified patients suffered from haematological diseases. Reported mortality reached 38.5%. By the fact of rising morbidity, unsatisfactory results of treatment and remaining high mortality of mucormycoses in immunocompromised patients, new therapeutic options are warrant. Isavuconazole, with its broad-spectrum activity, good safety profile and favourable pharmacokinetics, is a promising drug. However, further studies are necessary to confirm positive impact of isavuconazole on mucormycosis treatment in children.
- 23 July 2018
- Published by Springer Nature in Mycopathologia
- Vol. 184 (1) , 81-88
Open AccessIsavuconazole in a Successful Combination Treatment of Disseminated Mucormycosis in a Child with Acute Lymphoblastic Leukaemia and Generalized Haemochromatosis: A Case Report and Review of the Literature
Invasive mucormycosis in immunocompromised children is a life-threatening fungal infection. We report a case of a 7-year-old girl treated for acute lymphoblastic leukaemia complicated by disseminated mucormycosis during induction therapy. Microscopic examination of surgically removed lung tissue revealed wide, pauci-septate hyphae suggesting a Mucorales infection. This diagnosis was confirmed immunohistochemically and by PCR analysis followed by a final identification of Cunninghamella sp. The patient was treated successfully with surgical debridement and antifungal combination therapy with amphotericin B, caspofungin and isavuconazole. The use of isavuconazole in a child was not previously reported. Additionally, case reports concerning pulmonary mucormycoses in paediatric population published after 2010 were reviewed. Nineteen out of 26 identified patients suffered from haematological diseases. Reported mortality reached 38.5%. By the fact of rising morbidity, unsatisfactory results of treatment and remaining high mortality of mucormycoses in immunocompromised patients, new therapeutic options are warrant. Isavuconazole, with its broad-spectrum activity, good safety profile and favourable pharmacokinetics, is a promising drug. However, further studies are necessary to confirm positive impact of isavuconazole on mucormycosis treatment in children.